Lenercept

Lenercept is a recovery research peptide. Lenercept is a TNF-alpha inhibitor that has been investigated for its anti-inflammatory properties.

Lenercept is a recombinant fusion protein that functions as an inhibitor of TNF-alpha. It works by binding to TNF-alpha, thereby preventing it from interacting with its receptors and initiating inflammatory responses. Lenercept has been studied in clinical trials for conditions such as severe sepsis, early septic shock, rheumatoid arthritis, and multiple sclerosis. It reached Phase 3 development, with research focusing on its anti-inflammatory effects and pharmacokinetics.

1 Mechanism of action

TNF-alpha inhibitor (inhibitor)

2 Chemical and physical properties

3 Research studies (8)

1. Anti-inflammatory response after infusion of p55 soluble tumor necrosis factor receptor fusion protein for severe sepsis
   European cytokine network (2003) · RCT
2. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients
   Critical care medicine (2001) · RCT
3. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritis
   The Journal of rheumatology (2003) · RCT
4. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group
   Neurology (1999) · RCT
5. Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans
   Drug metabolism and disposition: the biological fate of chemicals (1999)
6. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials
   BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2002) · Review
7. [Multiple sclerosis. Current review of failed and discontinued clinical trials of drug treatment]
   Der Nervenarzt (2000) · Review
8. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis
   The Journal of rheumatology (2003) · RCT

4 Safety and risk profile

4.1 Regulatory status

Lenercept is currently classified as Phase 3 clinical trials. It has no approved human indication in the United States; availability elsewhere does not imply demonstrated safety or efficacy.

5 Frequently asked questions

What is Lenercept?

Lenercept is a recombinant fusion protein that acts as an inhibitor of TNF-alpha. It was developed to counteract inflammatory processes by blocking the activity of TNF-alpha.

How does Lenercept work?

Lenercept works by inhibiting TNF-alpha. It binds to TNF-alpha, which prevents this cytokine from interacting with its specific receptors. This action is intended to reduce the inflammatory responses mediated by TNF-alpha.

What has Lenercept been studied for?

Lenercept has been studied in clinical trials for several conditions, including severe sepsis, early septic shock, rheumatoid arthritis, and multiple sclerosis. Research has explored its potential anti-inflammatory effects in these contexts.

What is the regulatory status of Lenercept?

Lenercept has advanced to Phase 3 in its clinical development. This indicates that it has undergone extensive testing in human trials to evaluate its efficacy and safety for potential medical applications.

6 References

1. Lenercept — molecule record ChEMBL. View source
2. Lenercept — published literature (21 records) PubMed. View source

7 See also

• Peptide encyclopedia index
• Peptide reconstitution calculator
• Glossary of peptide research terms